Anavex Life Sciences

Anavex Life Sciences AVXL Stock

$0.74   -0.134987%
Add to favorites
Market Cap
$68.50M
LOW - HIGH [24H]
$0.72 - $0.78
VOLUME [24H]
$330.96K
P/E Ratio
0
Earnings per share
-$0.14
ISIN
US0327973006
Price   Prediction

Anavex Life Sciences Price Chart

Sorry, that's all we've gotfor now...

Anavex Life Sciences (AVXL) stock price today is 0.74 USD on Tech Market Large (-0.13% on the day). Updated .

Anavex Life Sciences AVXL Financial and Trading Overview

Anavex Life Sciences stock price 0.74 USD
Previous Close 0.93 USD
Open 0.94 USD
Bid 0.82 USD x 200
Ask 0.84 USD x 1100
Day's Range 0.8 - 0.95 USD
52 Week Range 0.8 - 5.36 USD
Volume 2.72M USD
Avg. Volume 1.05M USD
Market Cap 75.79M USD
Beta (5Y Monthly) 1.25
PE Ratio (TTM) N/A
EPS (TTM) -0.14 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est N/A

AVXL Valuation Measures

Enterprise Value -42537060 USD
Trailing P/E N/A
Forward P/E -1.4865454
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) 0.6740313
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA N/A

Trading Information

Anavex Life Sciences Stock Price History

Beta (5Y Monthly) 1.25
52-Week Change -73.91%
S&P500 52-Week Change 13.32%
52 Week High 5.36 USD
52 Week Low 0.8 USD
50-Day Moving Average 1.75 USD
200-Day Moving Average 2.9 USD

AVXL Share Statistics

Avg. Volume (3 month) 1.05M USD
Avg. Daily Volume (10-Days) 1.05M USD
Shares Outstanding 92.7M
Float 89.81M
Short Ratio 8.23
% Held by Insiders 1.95%
% Held by Institutions 41.51%
Shares Short 11.92M
Short % of Float 13.08%
Short % of Shares Outstanding 12.85%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor 1:4

Financial Highlights

Fiscal Year

Fiscal Year Ends September 30, 2025
Most Recent Quarter (mrq) June 30, 2026
Next Fiscal Year End September 30, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) 0%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -9.69%
Return on Equity (ttm) -12.80%

Income Statement

Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) N/A
EBITDA N/A
Net Income Avi to Common (ttm) -13022000 USD
Diluted EPS (ttm) -0.14
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 118.33M USD
Total Cash Per Share (mrq) 1.28 USD
Total Debt (mrq) 0 USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 15.619
Book Value Per Share (mrq) 1.213

Cash Flow Statement

Operating Cash Flow (ttm) -29291000 USD
Levered Free Cash Flow (ttm) -27060250 USD

Profile of Anavex Life Sciences

Country United States
State NY
City New York
Address 630 5th Avenue
ZIP 10111
Phone 844 689 3939
Website https://www.anavex.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 34

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

Q&A For Anavex Life Sciences Stock

What is a current AVXL stock price?

Anavex Life Sciences AVXL stock price today per share is 0.74 USD.

How to purchase Anavex Life Sciences stock?

You can buy AVXL shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Anavex Life Sciences?

The stock symbol or ticker of Anavex Life Sciences is AVXL.

Which industry does the Anavex Life Sciences company belong to?

The Anavex Life Sciences industry is Biotechnology.

How many shares does Anavex Life Sciences have in circulation?

The max supply of Anavex Life Sciences shares is 92.7M.

What is Anavex Life Sciences Price to Earnings Ratio (PE Ratio)?

Anavex Life Sciences PE Ratio is now.

What was Anavex Life Sciences earnings per share over the trailing 12 months (TTM)?

Anavex Life Sciences EPS is -0.14 USD over the trailing 12 months.

Which sector does the Anavex Life Sciences company belong to?

The Anavex Life Sciences sector is Healthcare.

Anavex Life Sciences AVXL included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24399.9 USD —
+0.29
2.79B USD — 24268.03 USD — 24538.78 USD — — 2.79B USD —
us US Tech Global Select Market Com NQGS US 11967.66 USD —
-0.14
— — 11954.49 USD — 12087.35 USD — — — —
us US Tech Biotechnology NBI US 6969.93 USD —
-0.68
— — 6959.96 USD — 7076.43 USD — — — —
us US Tech Health Care IXHC US 1324.33 USD —
-0.64
— — 1322.85 USD — 1342.46 USD — — — —
us US Tech Capital Market Composite RCMP US 108.59 USD —
-0.09
— — 108.35 USD — 109.95 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
$2.18T
Total marketcap
$68.49B
Total volume
BTC 58.12%   •   ETH 9.91%
Dominance
Select currency